| 12-LOX | 12-Lipoxygenase |
| 13R,14S-diHDHA | 13R,14S-dihydroxy-docosahexaenoic acid |
| 14S–HpDHA | 14S-hydroperoxy-docosahexaenoic acid |
| 15-epi-LXA4 | 15-epi-lipoxin A4 |
| 15-HPETE | 15-hydroperoxy-eicosatetraenoic acid |
| 15-LOX | 15-lipoxygenase |
| 15-PGDH | 15-prostaglandin dehydrogenase |
| 17-oxo-RvD1 | 17-oxoresolvin D1 |
| 17S-HpDHA | 17S-hydroperoxy-docosahexaenoic acid |
| 18R-HEPE | 18R-hydroxy-eicosapentaenoic acid |
| 18R-HpEPE | 18R-hydroxyperoxy-eicosapentaenoic acid |
| 5-LOX | 5-lipoxygenase |
| 8-oxo-RvD1 | 8-oxoresolvin D1 |
| AA | arachidonic acid |
| APC | antigen-presenting cell |
| ARG | arginase |
| AT-L | aspirin-triggered analogs |
| BDA-RvD1 | benzo-diacetylene-17R-RvD1 |
| benzo-LXA4 | benzo-lipoxin A4 |
| bFGF | basic fibroblast growth factor |
| BLT1 | leukotriene B4 receptor 1 |
| CAD | coronary artery disease |
| cAMP | cyclic adenosine monophosphate |
| CAMs | cell adhesion molecules |
| CANTOS | canakinumab anti-inflammatory thrombosis outcomes study |
| CCL2 | chemokine C-C motif ligand 2 |
| CCL20 | chemokine C-C motif ligand 20 |
| CCL3 | chemokine C-C motif ligand 3 |
| CCL4 | chemokine C-C motif ligand 4 |
| CCL8 | chemokine C-C motif ligand 8 |
| CCR5 | receptor 5 chemokine cysteine-cysteine cysteine |
| CD105 | cluster of differentiation 105 |
| CD11b | cluster of differentiation 11b |
| CD14 | cluster of differentiation 14 |
| CD19 | cluster of differentiation 19 |
| CD34 | cluster of differentiation 34 |
| CD73 | cluster of differentiation 73 |
| CD79α | cluster of differentiation 79 α |
| CD80 | cluster of differentiation 80 |
| CD83 | cluster of differentiation 83 |
| CD86 | cluster of differentiation 86 |
| CD90 | cluster of differentiation 90 |
| ChemR23 | chemerin receptor 23 |
| CIRT | cardiovascular Inflammation Reduction Trial |
| COX | cyclooxygenase |
| COX-2 | cyclooxygenase-2 |
| CRP | C-reactive protein |
| CRS | Cytokine Release Syndrome |
| CVDs | cardiovascular diseases |
| CXCL1 | chemokine C-X-C motif ligand-1 |
| CXCL2 | chemokine C-X-C motif ligand-2 |
| CXCL5 | chemokine C-X-C motif ligand-5 |
| CYP | cytochrome |
| CYP1A | cytochrome P450 1A |
| CYP2B1/2 | cytochrome P450 2B1/2 |
| CYP3A4 | cytochrome P450 3A4 |
| DAMPs | damage associated molecular patterns |
| DCs | dendritic cells |
| DHA | docosahexaenoic acid |
| E-CAMs | extracellular matrix adhesion molecules |
| ECM | extracellular matrix |
| EOR | eicosanoid oxidoreductase |
| EPA | eicosapentaenoic acid |
| ET-1 | endothelin-1 |
| FDA | food and drug administration |
| FGF | fibroblast growth factor |
| FPR2/ALX | formyl peptide receptor 2 |
| FPR2/ALX | formyl peptide receptor 2 |
| GPR18 | G protein-coupled receptor 18 |
| GPR32 | G protein-couple receptor 32 |
| GPR37 | G protein-coupled receptor 37 |
| HLA DR | human leukocyte antigen—DR isotype |
| IBS | innate immune system |
| ICAM-1 | intercellular adhesion molecule 1 |
| IFN | interferon |
| IFN-α/β | interferons alpha/beta |
| IFN-β | interferon β |
| IFN- γ | interferon γ |
| IL-1 | interleukin-1 |
| IL-1β | interleukin-1 β |
| IL-10 | interleukin-10 |
| IL-12 | interleukin-12 |
| IL-13 | Interleukin-13 |
| IL-17β | interleukin- 17 β |
| IL-2 | interleukin-2 |
| IL-23 | interleukin-23 |
| IL-6 | interleukin-6 |
| IRF7 | interferon regulatory factor 7 |
| LDL | low density lipoprotein |
| LGR6 | G protein-coupled receptor 6 |
| LOX | lipoxygenase |
| LPS | lipopolysaccharide |
| LXA4 | lipoxin A4 |
| LXB4 | lipoxin B4 |
| LXs | lipoxins |
| MAIT | mucosal Associated Innate T cells |
| MaR1 | maresin 1 |
| MaR2 | maresine 2 |
| MCP-1 | monocyte chemoattractant protein-1 |
| MHC | major histocompatibility molecules |
| miRNA | microRNA |
| MPL | monophosphoryl lipid A |
| MSCs | mesenchymal stem cells |
| MyD88/RAK/TRAF6 | myeloid differentiation factor 88/IL-1 receptor-associated kinase 1/tumor necrosis factor receptor-associated factor 6 |
| MyD88/TIRAP | myeloid differentiation factor 88/domain-containing adaptor protein |
| NF-κB | nuclear factor kappa B |
| NLRs | nod-like receptors |
| NO | nitric oxide |
| NOTCH-1 | neurogenic locus notch homolog protein 1 |
| NPD1 | neuroprotectin D1 |
| PAMPs | pathogen associated molecular patterns |
| PD1 | protectin D1 |
| PDGF | platelet-derived growth factor |
| PECAM-1 | platelet endothelial cell adhesion molecule-1 |
| PGDH | prostaglandin dehydrogenase |
| PGI2 | prostacyclin |
| PMN | polymorphonuclear neutrophils |
| PRRs | pattern recognition receptors |
| ROS | reactive oxygen species |
| RvD1 | resolvin D1 |
| RvD1-6 | D-series resolvins |
| RvD2 | resolvin D2 |
| RvD4 | resolvin D4 |
| RvD5 | resolvin D5 |
| RvE1 | resolvin E1 |
| RvE2 | resolvin E2 |
| RvE3 | resolvin E3 |
| SIE | specific immune system |
| SPM | specialized pro-resolving |
| T cruzi | Trypanosoma cruzi |
| TGF-β | transforming growth factor β |
| TGF-β3 | transforming growth factor β3 |
| TLR2 | toll-like receptor 2 |
| TLR4 | toll-like receptor 4 |
| TLRs | toll-like receptors |
| TNFα | tumor necrosis factor alpha |
| TRIF/TRAM | TIR-domain-containing adapter-inducing interferon-β/TRIF-related adaptor molecule |
| TSG-6 | tumor necrosis factor alfa stimulated gene 6 |
| TXA2 | thromboxane A2 |
| VCAM-1 | vascular cell adhesion molecule-1 |
| VEGF | vascular endothelial growth factor |
| VSMCs | vascular smooth muscle cells |